J2210 HCPCS code: Injection, methylergonovine maleate, up to 0.2 mg
J2210 is the HCPCS Level II code for injection, methylergonovine maleate, up to 0.2 mg. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met. The NCCI unit limit is 5 per day on outpatient hospital claims.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 1982-01-01 |
| Last action effective | 1997-01-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 5 | Clinical: Data |
| practitioner claims | 1 | Clinical: Data |
What changed for J2210
- 1982-01-01: J2210 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2210?
J2210 is the HCPCS Level II code for injection, methylergonovine maleate, up to 0.2 mg. Short descriptor: "Methylergonovin maleate inj".
Does Medicare cover J2210?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
How many units of J2210 can be billed per day?
5 on outpatient hospital claims; 1 on practitioner claims (NCCI medically unlikely edits).
Related J22 codes
- J2212 — Injection, methylnaltrexone, 0.1 mg
- J2246 — Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg
- J2247 — Injection, micafungin sodium (par pharm) not thereapeutically equivalent to j2248, 1 mg
- J2248 — Injection, micafungin sodium, 1 mg
- J2249 — Injection, remimazolam, 1 mg
- J2250 — Injection, midazolam hydrochloride, per 1 mg
- J2251 — Injection, midazolam in 0.9% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
- J2252 — Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
- J2253 — Injection, midazolam (seizalam), 1 mg
- J2260 — Injection, milrinone lactate, 5 mg
- J2265 — Injection, minocycline hydrochloride, 1 mg
- J2267 — Injection, mirikizumab-mrkz, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2210
- Watch J2210 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2210
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.